Select Achievements and Experience

Advanced nine medicines to the clinic, four of which have been commercialized:

Nutropin® Depot (protein)

Risperdal® Consta (small molecule)

Vivitrol® (small molecule)

Bydureon® (peptide)

At Alkermes, Inc., developed the first long-acting protein approved by the FDA and commercialized (Nutropin® Depot)

Led an international alliance of academic and industry partners while at Alnylam, Inc. that brought new nanotechnology-based RNA products to the clinic and enabled human clinical proof of concept for RNAi and a growing pipeline of RNA-based clinical programs

Advanced the first dual targeted RNAi based therapeutic to the clinic

Fellow, American Institute for Medical and Biological Engineering (AIMBE) www.aimbe.org